[1] |
RIZZETTO M, CANESE MG, ARICÒ S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers[J]. Gut, 1977, 18(12): 997-1003. DOI: 10.1136/gut.18.12.997.
|
[2] |
ZHANG Z, URBAN S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies[J]. J Hepatol, 2021, 74(3): 686-699. DOI: 10.1016/j.jhep.2020.11.032.
|
[3] |
STOCKDALE AJ, KREUELS B, HENRION MYR, et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis[J]. J Hepatol, 2020, 73(3): 523-532. DOI: 10.1016/j.jhep.2020.04.008.
|
[4] |
SHEN DT, GOYAL H, XU HG. Differences in delta virus hepatitis diagnosis methods and its effect on the hepatitis D prevalence[J]. Gut, 2020, 69(10): 1893. DOI: 10.1136/gutjnl-2019-320159.
|
[5] |
BUTI M, STEPANOVA M, PALOM A, et al. Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B[J]. JHEP Rep, 2021, 3(3): 100280. DOI: 10.1016/j.jhepr.2021.100280.
|
[6] |
URBAN S, NEUMANN-HAEFELIN C, LAMPERTICO P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease[J]. Gut, 2021, 70(9): 1782-1794. DOI: 10.1136/gutjnl-2020-323888.
|
[7] |
MENTHA N, CLÉMENT S, NEGRO F, et al. A review on hepatitis D: From virology to new therapies[J]. J Adv Res, 2019, 17: 3-15. DOI: 10.1016/j.jare.2019.03.009.
|
[8] |
KOH C, HELLER T, GLENN JS. Pathogenesis of and new therapies for hepatitis D[J]. Gastroenterology, 2019, 156(2): 461-476. e1. DOI: 10.1053/j.gastro.2018.09.058.
|
[9] |
ARAGONA M, MACAGNO S, CAREDDA F, et al. Serological response to the hepatitis delta virus in hepatitis D[J]. Lancet, 1987, 1(8531): 478-480. DOI: 10.1016/s0140-6736(87)92090-3.
|
[10] |
NOUREDDIN M, GISH R. Hepatitis delta: Epidemiology, diagnosis and management 36 years after discovery[J]. Curr Gastroenterol Rep, 2014, 16(1): 365. DOI: 10.1007/s11894-013-0365-x.
|
[11] |
CHEN HY, SHEN DT, JI DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: A systematic review and meta-analysis[J]. Gut, 2019, 68(3): 512-521. DOI: 10.1136/gutjnl-2018-316601.
|
[12] |
ROGGENBACH I, CHI XM, LEMPP FA, et al. HDV seroprevalence in HBsAg-positive patients in China occurs in hotspots and is not associated with HCV mono-infection[J]. Viruses, 2021, 13(9): 1799. DOI: 10.3390/v13091799.
|
[13] |
CHEN XH, OIDOVSAMBUU O, LIU P, et al. A novel quantitative microarray antibody capture assay identifies an extremely high hepatitis delta virus prevalence among hepatitis B virus-infected mongolians[J]. Hepatology, 2017, 66(6): 1739-1749. DOI: 10.1002/hep.28957.
|
[14] |
WU SS, ZHANG Y, TANG YY, et al. Molecular epidemiology and clinical characteristics of hepatitis delta virus (HDV) infected patients with elevated transaminases in Shanghai, China[J]. BMC Infect Dis, 2020, 20(1): 565. DOI: 10.1186/s12879-020-05275-1.
|
[15] |
CHEMIN I, PUJOL FH, SCHOLTÈS C, et al. Preliminary evidence for hepatitis delta virus exposure in patients who are apparently not infected with hepatitis B virus[J]. Hepatology, 2021, 73(2): 861-864. DOI: 10.1002/hep.31453.
|